secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2021-10-01T23:59:59+00:00
Accession:  0000950170-21-001975
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ziopharm CAO Kevin Lafond to exit Nov 8 amid restructuring
----------------------------------------------------------

- Kevin G. Lafond, Sr. VP Finance, CAO and Treasurer, separating effective Nov 8, 2021.
- Severance payment of approximately $0.2 million upon separation.
- Departure is part of a restructuring to advance the TCR program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000095017021001975/0000950170-21-001975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000095017021001975/ziop-20211001.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer